Daniel Devine & Co’s Novartis NVS Stock Holding History

Daniel Devine & Co’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$1.39M	Sell	20,590 -3,571	-15%	-$246K	1.11%	24
2018 Q1	$1.75M	Hold	24,161	–	–	1.42%	21
2017 Q4	$1.82M	Hold	24,161	–	–	1.32%	17
2017 Q3	$1.86M	Hold	24,161	–	–	1.42%	14
2017 Q2	$1.81M	Sell	24,161 -2,232	-8%	-$158K	1.47%	15
2017 Q1	$1.76M	Sell	26,393 -9,933	-27%	-$662K	1.44%	15
2016 Q4	$2.37M	Hold	36,326	–	–	1.69%	20
2016 Q3	$2.57M	Hold	36,326	–	–	1.73%	17
2016 Q2	$2.69M	Hold	36,326	–	–	1.83%	15
2016 Q1	$2.36M	Buy	36,326 +18,191	+100%	+$1.24M	1.54%	16
2015 Q4	$1.4M	Hold	18,135	–	–	0.92%	34
2015 Q3	$1.49M	Hold	18,135	–	–	1.06%	27
2015 Q2	$1.6M	Hold	18,135	–	–	1.1%	26
2015 Q1	$1.6M	Hold	18,135	–	–	1.07%	27
2014 Q4	$1.51M	Buy	+18,135	New	+$1.5M	1.08%	24

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Daniel Devine & Co's NVS Position: Q2 2018 in Review

Daniel Devine & Co reduced its Novartis (NVS) stake by 15% in Q2 2018, selling an estimated $246K and leaving 20,590 shares worth $1.39M. The position accounts for 1.11% of the portfolio, ranked #24.

Daniel Devine & Co first reported a position in NVS in Q4 2014 and has held it in 15 quarters since. The position peaked at $2.69M in Q2 2016. 988 funds tracked by Wall St. Rank hold NVS as of Q2 2018.

Daniel Devine & Co held 20,590 shares of Novartis worth $1.39M as of Q2 2018.
Daniel Devine & Co sold 3,571 Novartis shares in Q2 2018, an estimated $246K.
Novartis made up 1.11% of Daniel Devine & Co's portfolio in Q2 2018, its #24 holding.
Daniel Devine & Co first reported a position in Novartis in Q4 2014 and has held it in 15 quarters since.
Daniel Devine & Co's Novartis position peaked at $2.69M in Q2 2016.
988 funds tracked by Wall St. Rank held Novartis as of Q2 2018.

Based on Daniel Devine & Co's 13F filing for Q2 2018, filed 18 Jul 2018.